Added to YB: 2025-04-01
Pitch date: 2025-02-13
SWTX [bullish]
SpringWorks Therapeutics, Inc.
-20.23%
current return
Author Info
No bio for this author
Company Info
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
Market Cap
$3.5B
Pitch Price
$58.91
Price Target
70.00 (+49%)
Dividend
N/A
EV/EBITDA
-11.96
P/E
-13.77
EV/Sales
14.41
Sector
Biotechnology
Category
special_situation
SpringWorks Therapeutics, Inc. - $SWTX
SWTX: Merck KGAA in advanced talks to acquire. FDA approval of Gomelki (NF1-PN drug) likely key condition. Deal expected soon at $70+/share (50-100% premium). Two potential blockbusters: Ogsiveo ($172M 2024) & Gomelki. Downside $45-50 if no deal. 95% deal odds. Potential bidding war upside.
Read full article (6 min)